SOURCE: NanoLogix, Inc.

February 09, 2007 09:31 ET

NanoLogix Achieves Initial Sales of Hydrogen Powered Generators

SHARON, PA -- (MARKET WIRE) -- February 9, 2007 -- NanoLogix, Inc. (PINKSHEETS: NNLX), an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes, announced today the initial sale of hydrogen powered generator engines, which had been converted from gas engines. This was done in conjunction with Precision Performance Co. of Brookfield, Ohio, a private company.

Mitchell Felder, M.D., NanoLogix Chairman of the Board and Chief Executive Officer, stated, "I am pleased our research and development have enabled us to reach this company milestone. We have successfully converted gas powered engines to hydrogen power. These initial sales will be recognized in the first quarter of this year. Our sales initiatives will include small and large projects, including motorcycles, diesel engines and numerous combustion engines."

Precision Performance Co. in partnership with NanoLogix has successfully converted gas powered engines to hydrogen power on numerous commercial engines. NanoLogix has retained Precision Performance Co. to handle conversion specifications based on the NanoLogix pending intellectual property in this field of endeavor.

About NanoLogix, Inc.:

NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • Contacts:
    Investor Relations.
    Andrew Barwicki
    Email Contact

    NanoLogix, Inc.
    87 Stambaugh Avenue, Suite Two
    Sharon, PA 16146
    Telephone: 724-346-1302
    Fax: 724-346-9596